このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

NanoViricides 将来の成長

Future 基準チェック /06

NanoViricidesは、7.8%と72.9%でそれぞれ年率7.8%で利益と収益が成長すると予測される一方、EPSはgrowで16.1%年率。

主要情報

7.8%

収益成長率

16.1%

EPS成長率

Biotechs 収益成長	24.1%
収益成長率	63.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	20 May 2024

今後の成長に関する最新情報

Recent updates

We Think NanoViricides (NYSEMKT:NNVC) Can Afford To Drive Business Growth

Feb 18

業績と収益の成長予測

NYSEAM:NNVC - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2027	7	-6	-4	-4	1
6/30/2026	3	-8	-5	-5	1
6/30/2025	N/A	-11	-9	-8	2
6/30/2024	N/A	-7	-6	-6	2
3/31/2024	N/A	-10	-6	-6	N/A
12/31/2023	N/A	-9	-6	-6	N/A
9/30/2023	N/A	-9	-6	-6	N/A
6/30/2023	N/A	-9	-6	-6	N/A
3/31/2023	N/A	-7	-6	-6	N/A
12/31/2022	N/A	-7	-6	-5	N/A
9/30/2022	N/A	-7	-7	-6	N/A
6/30/2022	N/A	-8	-6	-6	N/A
3/31/2022	N/A	-8	-7	-7	N/A
12/31/2021	N/A	-9	-7	-7	N/A
9/30/2021	N/A	-9	-7	-7	N/A
6/30/2021	N/A	-9	-8	-8	N/A
3/31/2021	N/A	-9	-8	-8	N/A
12/31/2020	N/A	-15	-9	-9	N/A
9/30/2020	N/A	-14	-8	-7	N/A
6/30/2020	N/A	-13	-7	-7	N/A
3/31/2020	N/A	-14	-7	-7	N/A
12/31/2019	N/A	-8	-6	-6	N/A
9/30/2019	N/A	-8	-7	-7	N/A
6/30/2019	N/A	-8	-7	-7	N/A
3/31/2019	N/A	-8	-9	-9	N/A
12/31/2018	N/A	-8	-8	-8	N/A
9/30/2018	N/A	-8	-7	-7	N/A
6/30/2018	N/A	-9	-8	-8	N/A
3/31/2018	N/A	-9	-6	-5	N/A
12/31/2017	N/A	-10	N/A	-6	N/A
9/30/2017	N/A	-9	N/A	-7	N/A
6/30/2017	N/A	-10	N/A	-8	N/A
3/31/2017	N/A	-9	N/A	-8	N/A
12/31/2016	N/A	-11	N/A	-9	N/A
9/30/2016	N/A	-12	N/A	-7	N/A
6/30/2016	N/A	-11	N/A	-7	N/A
3/31/2016	N/A	-10	N/A	-7	N/A
12/31/2015	N/A	-5	N/A	-6	N/A
9/30/2015	N/A	-4	N/A	-6	N/A
6/30/2015	N/A	-2	N/A	-6	N/A
3/31/2015	N/A	-8	N/A	-6	N/A
12/31/2014	N/A	-7	N/A	-6	N/A
9/30/2014	N/A	-6	N/A	-7	N/A
6/30/2014	N/A	-14	N/A	-6	N/A
3/31/2014	N/A	-9	N/A	-7	N/A
12/31/2013	N/A	-14	N/A	-7	N/A

アナリストによる今後の成長予測

収入対貯蓄率: NNVC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: NNVC今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: NNVC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: NNVC来年は収益がないと予測されています。

高い収益成長: NNVC来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: NNVCの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

NanoViricides 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased by 38% to US$5.25

Recent updates

Nanoviricides, Inc. Reports Nv-387 Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

Nanoviricides, Inc. Reports Clinical Stage Lead Nanoviricide Broad-Spectrum Antiviral Drug Candidate Orally Administered Nv-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

NanoViricides, Inc. Announces A Novel Broad-Spectrum Antiviral with Activity Against RSV

NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox

NanoViricides, Inc. Reports That the Phase I NV-387 Clinical Trial Is Completed Successfully and Data Lock Is Expected Soon

New major risk - Financial position

NanoViricides, Inc. Announces Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics

Nanoviricides, Inc. Reports Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the Nanoviricides Ultra-Broad-Spectrum Antiviral Drug Nv-2 with No Adverse Events Found

Insufficient new directors

NanoViricides, Inc., Annual General Meeting, Jan 13, 2024

NanoViricides, Inc. Announces the Single-Ascending Dose Part of the Phase 1A/1B Human Clinical Trial of NV-CoV-2

Nanoviricides, Inc. Announces Broad-Spectrum Antiviral Nv-387 (Nv-Cov-2) in Phase 1A/1B Clinical Trial Is Highly Effective in an Animal Model for Mpox and Smallpox Drug Development

Nanoviricides, Inc. Reports the Phase 1A/1B Human Clinical Trial of Nv-Cov-2

New major risk - Revenue and earnings growth

Nanoviricides, Inc.'S Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in A Lethal Lung Disease Animal Model, Reports Nanoviricides

Nanoviricides, Inc. Reports Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 Is Progressing Well

Nanoviricides, Inc. Announces Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun

New major risk - Share price stability

Price target decreased by 38% to US$5.25

NanoViricides, Inc., Annual General Meeting, Feb 07, 2023

NanoViricides, Inc., Annual General Meeting, Dec 17, 2022

NanoViricides, Inc. announced delayed annual 10-K filing

NanoViricides, Inc. Reports Advantages Gained by Remdesivir Encapsulation

NanoViricides, Inc.(NYSEAM:NNVC) dropped from Russell Microcap Growth Index

We Think NanoViricides (NYSEMKT:NNVC) Can Afford To Drive Business Growth

New 90-day high: US$5.49

Consultant has left the company

New 90-day high: US$4.43

New 90-day low: US$3.08

Nanoviricides, Inc. Announces Board Changes

NanoViricides, Inc. announced delayed annual 10-K filing

New 90-day low: US$3.81

NanoViricides, Inc. Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19

New 90-day low - US$5.57

NanoViricides, Inc. has completed a Follow-on Equity Offering in the amount of $10 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘